Pilot scheme for risk sharing in the reimbursement system as part of the Growth Plan for Life Science
The Danish government has now published its life science growth plan, which aims at making Denmark a leading life science nation in Europe.
The growth plan is based on the recommendations submitted by the Growth Team for Life Science. Plesner has previously reported on the topic
The growth plan contains 36 initiatives in 6 key areas. One of the many initiatives is a pilot scheme for risk sharing in the drug reimbursement system. In the current reimbursement system the Danish Medicines Agency has the possibility to refuse reimbursement to companies if the specific medicines can potentially be prescribed to more patients than those in the original target group. The government will now propose a pilot project, where a risk sharing scheme will be introduced for two chosen medicines, and where the company will cover the additional expenses associated with reimbursements if the product turns out to be used to treat more patients than originally estimated. The scheme will be evaluated in 2021.
The Growth Plan can be accessed here (in Danish):
The factsheet in English can be accessed here
A prior version of this post was originally published by the same authors in Practical Law – Life Sciences, March 2017 Issue (Thomson Reuters).